🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementSulfur burps on tirzepatide — need advice

Sulfur burps on tirzepatide — need advice

MaxMetOK Mon, Feb 2, 2026 at 5:45 PM 39 replies 1,218 viewsPage 1 of 8
MaxMetOK
Member
312
1,123
Dec 2024
Oklahoma
Feb 2, 2026 at 5:45 PM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

What I actually want to know is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

I have searched first, so if this is covered somewhere point me at it and I will read it.

31 1PharmHunterJen, TomTeleRx, DoseLogDan and 28 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Feb 2, 2026 at 7:33 PM#2

Taking the question as asked, rather than the general version of it. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

30 0Dr.PulmRoch, maya_sedona, stefan_berlin and 27 others
Reply Quote Save Share Report
amy_econ_NJ
Member
567
2,567
May 2024
Princeton, NJ
Feb 2, 2026 at 9:21 PM#3
BethLabQueen said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

29 24sean_dublin, hannah_MT, Dr.SportsMedIN and 26 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Feb 2, 2026 at 11:09 PM#4
MaxMetOK said:
The nausea I get is not really nausea, it is an aversion.

This matches mine closely enough to be worth saying so. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

28 23NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 25 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Feb 3, 2026 at 9:46 AM#5

From the other side of the consultation, briefly. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

27 22mike_mealprep, NicoleRaleigh, james_edin and 24 others
Reply Quote Save Share Report
1238

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register